Patient Forecast Projects Significant Expansion of Drug-Treated Population, But Only For a Limited Time Due to a Cohort Effect, According to a New
Report from Decision Resources
WALTHAM, Mass., Sept. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, has found that a significant proportion of hepatitis C virus (HCV) patients do not achieve a sustained virologic response or are not able to tolerate current first-line treatment. According to the new report entitled Hepatitis C Virus Patient Flow Model and Treatment Algorithm, although currently available therapies can cure HCV, these agents are effective in only about half of all patients who receive therapy. The lack of available efficacious second- and third-line therapies leads to the accumulation of patients who are non-responsive to first-line therapy. Because HCV is not a highly fatal disease, this growing population is awaiting the launch of novel therapies and represents an important segment in the HCV market.
Hepatitis C virus represents a large commercial opportunity for drug developers due to its high prevalence, the relatively poor efficacy and side effects of current therapies and its large undiagnosed and under treated population.
"A sizeable cohort of the HCV-infected patients is aging, developing progressive liver disease, and is awaiting the introduction of several innovative new therapies in late-stage development," said John Lebbos, M.D., therapeutic area director at Decision Resources. "However, over the longer term, the size of the candidate population for treatment will be limited due to the dramatic decreases in the incidence of HCV that have been achieved as well as the improved efficacy of novel agents."
Based on this report, Decision Resources is offering an exclusive, in-
depth webinar entitled Hepatitis C Virus: Forecasting the Drug-Treated and
|SOURCE Decision Resources, Inc.|
Copyright©2007 PR Newswire.
All rights reserved